RSA3 Antibody

What is RSK3 and what cellular functions does it mediate?

RSK3, also known as RPS6KA2 (Ribosomal protein S6 kinase alpha-2), is a serine/threonine-protein kinase that functions downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling pathways. It mediates mitogenic and stress-induced activation of transcription factors, regulates translation, and promotes cellular proliferation, survival, and differentiation. Research indicates it may function as a tumor suppressor in epithelial ovarian cancer cells. RSK3 is also known by several other names including MAPKAPK1C, S6K-alpha-2, 90 kDa ribosomal protein S6 kinase 2, and p90RSK2 .

How are RSK3 antibodies typically generated for research applications?

RSK3 antibodies used in research are typically generated through traditional immunization methods. For polyclonal antibodies, researchers immunize animals (commonly rabbits) with a specific immunogen corresponding to a recombinant fragment protein within human RPS6KA2. After achieving the desired antibody titer in serum, the antibodies are purified directly from the serum. For monoclonal antibodies, the process involves immunizing animals, extracting B cells from the spleen, and fusing them with immortal myeloma cells to create hybridomas. These hybridomas undergo single-cell cloning (usually by limiting dilution) to ensure they are truly monoclonal and maintain stable antibody secretion .

What are the key differences between polyclonal and monoclonal RSK3 antibodies?

Polyclonal RSK3 antibodies (like ab227230) contain a mixture of antibodies that recognize multiple epitopes on the RSK3 protein, offering broader antigen recognition but potentially greater batch-to-batch variability. They are typically produced in rabbits or larger mammals. Monoclonal antibodies, in contrast, recognize a single epitope, providing greater specificity but potentially more limited recognition patterns. Monoclonal antibodies require hybridoma technology involving B cell fusion with myeloma cells followed by careful screening and selection. For research applications requiring detection of complex protein conformations or enhanced signal detection, polyclonal antibodies might be preferable, while applications demanding high specificity for a particular epitope would benefit from monoclonal antibodies .

What validated applications exist for RSK3 antibodies in experimental research?

Based on published research, RSK3 antibodies have been validated for Western Blotting (WB) applications. Specifically, the rabbit polyclonal RSK3 antibody (ab227230) has been validated for detecting RSK3 in human and mouse samples. When using this antibody for Western blotting, a band at approximately 83 kDa (the predicted molecular weight of RSK3) is observed when testing human liver hepatocellular carcinoma cell line (HepG2) whole cell lysate. The antibody has demonstrated effectiveness at a 1/1000 dilution when used with 30 μg of total protein loaded .

How should researchers design positive and negative controls for RSK3 antibody experiments?

For positive controls, researchers should use:

• HepG2 cell lysates, which have been validated to express detectable levels of RSK3

• Recombinant RSK3/RPS6KA2 protein

• Tissues known to express significant RSK3 levels

For negative controls, researchers should consider:

• Cell lines with confirmed low or no RSK3 expression

• RSK3 knockout cell lines (generated via CRISPR-Cas9 or similar technology)

• Using a deletion mutant antibody (like ΔRSC3 in other antibody research systems) that lacks binding capability to the target

• Pre-absorption of the antibody with the immunizing peptide

Including parallel experiments with non-specific IgG from the same species (rabbit IgG for polyclonal RSK3 antibodies) at the same concentration is essential for distinguishing specific from non-specific signals .

What species reactivity has been confirmed for RSK3 antibodies?

The RSK3 antibody (ab227230) has been specifically tested and confirmed to react with both human and mouse samples. This cross-reactivity makes it valuable for comparative studies across these two commonly used experimental systems. While the antibody may potentially react with other species that share high sequence homology with human and mouse RSK3, such cross-reactivity would need experimental validation before application in research contexts .

What are the optimal conditions for Western blotting with RSK3 antibody?

Based on validated protocols, researchers should follow these guidelines for optimal Western blotting with RSK3 antibody:

Researchers should note that the relatively high molecular weight of RSK3 (83 kDa) requires appropriate gel percentage selection (7.5%) to ensure optimal protein separation. Additionally, extended transfer times may be necessary for complete transfer of this higher molecular weight protein .

How can researchers verify RSK3 antibody specificity in their experimental system?

To verify RSK3 antibody specificity, researchers should employ multiple complementary approaches:

• Peptide competition assay: Pre-incubate the antibody with excess immunizing peptide before use in the intended application. Specific staining/binding should be blocked.

• Molecular weight verification: Confirm that the observed band in Western blotting matches the predicted molecular weight of RSK3 (83 kDa).

• siRNA or CRISPR knockout validation: Apply the antibody to detect RSK3 in cells where the protein has been knocked down or knocked out. Signal reduction or elimination confirms specificity.

• Immunoprecipitation followed by mass spectrometry: Precipitate the target using the RSK3 antibody and confirm identity via mass spectrometry.

• Cross-validation with multiple antibodies: Use alternative antibodies targeting different epitopes of RSK3 to confirm concordant results.

These methods collectively provide robust validation of antibody specificity, which is crucial for accurate data interpretation .

How can RSK3 antibodies be utilized to investigate ERK signaling pathway interactions?

RSK3 antibodies can be employed to study ERK pathway dynamics through several sophisticated approaches:

• Co-immunoprecipitation studies: Use RSK3 antibodies to pull down the protein complex and analyze interacting partners within the ERK signaling cascade through Western blotting or mass spectrometry.

• Phosphorylation state analysis: Combine RSK3 antibodies with phospho-specific antibodies to track activation states following pathway stimulation or inhibition with compounds like MEK/ERK inhibitors.

• Chromatin immunoprecipitation (ChIP): Apply RSK3 antibodies in ChIP experiments to identify genomic regions and transcription factors targeted by RSK3 downstream of ERK signaling.

• Proximity ligation assays (PLA): Combine RSK3 antibodies with antibodies against suspected interaction partners to visualize and quantify protein-protein interactions in situ.

• Real-time signaling dynamics: Use RSK3 antibodies in conjunction with live-cell imaging techniques to track pathway activation, translocation, and protein interactions following stimulation.

These approaches can reveal how RSK3 functions within the broader context of ERK pathway regulation of cellular processes including proliferation, survival, and differentiation .

What is the role of RSK3 as a potential tumor suppressor and how can antibodies help investigate this function?

Research suggests RSK3 may function as a tumor suppressor specifically in epithelial ovarian cancer cells. RSK3 antibodies are critical tools for investigating this tumor suppressor function through several research approaches:

• Expression profiling: Researchers can use immunohistochemistry with RSK3 antibodies to compare expression levels between normal ovarian tissue and cancer specimens across different grades and stages.

• Functional domain mapping: By combining RSK3 antibodies with deletion or mutation constructs, researchers can identify which domains are essential for the tumor suppressor function.

• Protein-protein interaction networks: RSK3 antibodies enable the identification of cancer-specific interaction partners through techniques like co-immunoprecipitation followed by mass spectrometry.

• Post-translational modification analysis: Phospho-specific antibodies can be used alongside RSK3 antibodies to determine how activation state correlates with tumor suppressor function.

• Therapeutic response prediction: RSK3 expression and activation status (detected via antibodies) may serve as biomarkers for predicting response to targeted therapies affecting the ERK pathway.

This research direction has significant implications for understanding ovarian cancer pathogenesis and potentially developing novel therapeutic approaches .

What are common challenges when using RSK3 antibodies and how can they be addressed?

When facing these challenges, researchers should systematically optimize each experimental parameter and include appropriate controls to ensure reliable results .

How should researchers interpret contradictory results between different RSK3 antibody-based detection methods?

When faced with contradictory results between different detection methods using RSK3 antibodies, researchers should follow this systematic approach:

• Epitope differences: Different antibodies may recognize distinct epitopes that could be differentially accessible depending on protein conformation, post-translational modifications, or protein-protein interactions.

• Methodological sensitivity thresholds: Methods like flow cytometry, immunohistochemistry, and Western blotting have different sensitivity thresholds and sample preparation requirements that affect detection.

• Antibody validation status: Evaluate the validation data for each antibody used. Some may be validated for certain applications but not others.

• Orthogonal validation: Employ non-antibody-based methods (e.g., mass spectrometry, RNA-seq) to resolve contradictions.

• Biological context: Consider cell type-specific or context-dependent expression and modification patterns of RSK3.

• Technical replication: Repeat experiments with standardized protocols across methods to determine if discrepancies are technical or biological in nature.

Ultimately, contradictory results often reveal important biological insights about protein conformation, localization, or modification states that may be functionally relevant .

What are the advantages and limitations of newer antibody generation technologies for RSK3 research?

Modern antibody generation technologies offer several advantages and limitations specifically relevant to RSK3 research:

Researchers studying RSK3 should select the antibody generation technology based on their specific experimental needs, considering factors such as required specificity, application compatibility, and consistency requirements .

How can researchers assess and compare the quality of different commercially available RSK3 antibodies?

To effectively evaluate and compare RSK3 antibodies from different sources, researchers should assess:

• Validation documentation:

  • Verify the antibody has been tested specifically for RSK3 detection

  • Review validation data for your intended application (e.g., Western blot, IHC)

  • Check if validation includes positive controls (e.g., HepG2 cell lysates for RSK3)

  • Confirm testing in relevant species (human, mouse)

• Technical specifications:

  • Antibody type (polyclonal vs. monoclonal)

  • Host species and isotype

  • Immunogen details (specific region of RSK3 used)

  • Predicted molecular weight detection (83 kDa for RSK3)

• Independent validation:

  • Search literature for independent use of the antibody

  • Check antibody validation resources and databases

  • Consider performing comparative testing of multiple antibodies

• Application-specific data:

  • Review recommended dilutions for your application

  • Assess sample preparation compatibility

  • Check for known cross-reactivity with related proteins (other RSK family members)

This systematic assessment enables researchers to select the most appropriate RSK3 antibody for their specific research requirements .